Continuous ultrafiltration for congestive heart failure: the CUORE trial

Area of Science:

• Cardiology
• Nephrology
• Critical Care Medicine

Background:

• Limited data exists comparing ultrafiltration and standard medical therapy for severe congestive heart failure (HF).
• This study addresses the comparison in hospitalized HF patients with overt fluid overload.

Purpose of the Study:

• To compare the efficacy of ultrafiltration versus conventional therapy as a first-line treatment for severe congestive HF.
• To evaluate rehospitalization rates and clinical outcomes in HF patients with fluid overload.

Main Methods:

• 56 patients with congestive HF were randomized into two groups: standard medical therapy (control) and ultrafiltration.
• The primary endpoint was 1-year rehospitalizations for congestive HF.
• Secondary outcomes included renal function, medication dosage, B-type natriuretic peptide levels, and mortality.

Main Results:

• Ultrafiltration group showed a significantly lower incidence of HF rehospitalizations (HR 0.14, P = .002) over 1 year.
• Benefits included more stable renal function, unchanged furosemide dose, and lower B-type natriuretic peptide levels.
• Mortality rates at 1 year were 30% in the ultrafiltration group versus 44% in the control group (P = .33).

Conclusions:

• First-line ultrafiltration in severe fluid overload HF patients leads to prolonged clinical stabilization.
• Ultrafiltration is associated with greater freedom from rehospitalization for congestive HF.
• Ultrafiltration demonstrates a potential benefit in managing severe fluid overload in heart failure.